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Kogawa M, Khalid KA, Wijenayaka AR, Ormsby RT, Ev-
dokiou A, Anderson PH, Findlay DM, Atkins GJ. Recombinant
sclerostin antagonizes effects of ex vivo mechanical loading in tra-
becular bone and increases osteocyte lacunar size. Am J Physiol Cell
Physiol 314: C53–C61, 2018. First published October 4, 2017; doi:
10.1152/ajpcell.00175.2017.—Sclerostin has emerged as an important
regulator of bone mass. We have shown that sclerostin can act by
targeting late osteoblasts/osteocytes to inhibit bone mineralization and
to upregulate osteocyte expression of catabolic factors, resulting in
osteocytic osteolysis. Here we sought to examine the effect of exog-
enous sclerostin on osteocytes in trabecular bone mechanically loaded
ex vivo. Bovine trabecular bone cores, with bone marrow removed,
were inserted into individual chambers and subjected to daily episodes
of dynamic loading. Cores were perfused with either osteogenic media
alone or media containing human recombinant sclerostin (rhSCL) (50
ng/ml). Loaded control bone increased in apparent stiffness over time
compared with unloaded bone, and this was abrogated in the presence
of rhSCL. Loaded bone showed an increase in calcein uptake as a
surrogate of mineral accretion, compared with unloaded bone, in
which this was substantially inhibited by rhSCL treatment. Sclerostin
treatment induced a significant increase in the ionized calcium con-
centration in the perfusate and the release of -CTX at several time
points, an increased mean osteocyte lacunar size, indicative of osteo-
cytic osteolysis, and the expression of catabolism-related genes.
Human primary osteocyte-like cultures treated with rhSCL also re-
leased -CTX from their matrix. These results suggest that osteocytes
contribute directly to bone mineral accretion, and to the mechanical
properties of bone. Moreover, it appears that sclerostin, acting on
osteocytes, can negate this effect by modulating the dimensions of the
lacunocanalicular porosity and the composition of the periosteocyte
matrix.
sclerostin; mechanical loading; osteocyte; osteocytic osteolysis; bone
mineralization
INTRODUCTION
Bone is a metabolically active organ that undergoes contin-
uous remodeling (20, 44), which is necessary to maintain the
structural integrity of the skeleton (8, 50). A lack of loading
causes an imbalance of this remodeling, favoring bone
resorption over bone formation. Accumulated evidence sug-
gests that osteocytes play key roles in the regulation of bone
remodeling by controlling the function of the other cell
types in bone, such as activating osteoblastogenesis or
osteoclastogenesis in response to increased or decreased
strains, respectively, imposed by mechanical loading (1, 21,
22, 24, 33, 34, 42). In particular, osteocytes have a key role
in mechanotransduction, the mechanism by which mechan-
ical load applied to bone is converted to biological signals
for maintaining appropriate strength and mechanical integ-
rity of the bone (15, 16, 47). Although it is well established
that loading has anabolic effects on bone, inducing en-
dosteal and periosteal bone formation, the effects of loading
on the bone matrix are less clear.
Mature osteocytes embedded in the mineralized bone matrix
secrete sclerostin, the product of the sclerosteosis (SOST) gene
(38), which is a potent anti-anabolic factor of bone formation
(9, 25–27, 51, 55). The SOST gene appears to be mechanosen-
sitive, with sclerostin production reported to be suppressed in
a mouse ulnar loading model (45). Tu and coworkers (49)
reported that cyclic ulnar loading-induced bone formation in
mice did not occur in animals transgenic for human SOST
expression, where effective sclerostin levels remained abnor-
mally high after loading, indicating that the downregulation of
sclerostin expression was a prerequisite for loading-induced
bone growth. Consistent with this, Moustafa and colleagues
(31) reported in a mouse tibial axial loading model that the
suppression of Sost colocalized with regions of increased strain
and increased bone formation. In contrast, Sost expression was
reported to increase in response to unloading of bone (31, 45).
Lin and coworkers (28) reported that unloading-induced bone
loss was sclerostin-dependent, as Sost-null mice were resistant
to this effect. A study by Macias and colleagues (30) suggested
that the relationship between Sost expression and loading is
more complex, as in a rat hindlimb unloading model, whereas
Sost mRNA levels increased in diaphyseal cortical bone in
response to unloading, they decreased in metaphyseal cortical
and trabecular bone. Despite this, it appears that pharmacolog-
ical inhibition of sclerostin prevents and reverses unloading-
induced bone loss in both cortical and trabecular bone com-
partments, as shown in the mouse hindlimb tail suspension
model (48).
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Recent evidence from our group suggests that, in bone
formation, mature cells of the late osteoblast to osteocyte
stages are key cellular targets for the action of sclerostin (2, 23,
54). We reported that sclerostin induced the expression of
mineralization inhibitory peptides, termed MEPE-ASARM
(acidic, serine, aspartate-rich, MEPE-associated) peptides, de-
rived from the proteolytic processing of matrix extracellular
phosphoglycoprotein (MEPE) (2). We also showed that
sclerostin could act as a catabolic agent by stimulating osteo-
cyte support of osteoclastic activity via the receptor-activated
nuclear factor kappa-B ligand (RANKL) signaling pathway
(54), which could explain the rapid and marked effect on bone
resorption when sclerostin is inhibited clinically using a
sclerostin-neutralizing antibody (36). We also demonstrated a
direct catabolic action of sclerostin in promoting osteocytic
osteolysis, increasing osteocyte expression of carbonic anhy-
drase II (CA2) (23), cathepsin K (CTSK), and matrix metal-
lopeptidase-13 (MMP13). Treatment with exogenous scleros-
tin resulted in an increase in the size of osteocyte lacunae in
human trabecular bone over 7 days in static, mechanically
nonloaded culture ex vivo (23). Together, these findings pro-
vide evidence that sclerostin acts on osteocytes to control bone
volume via bone formation and bone remodeling, and on bone
matrix mineralization by regulating osteocytic osteolysis.
In this study, we further investigated the effects of sclerostin
on osteocytes in the context of their natural conformation
within bone matrix, largely free of other cell types and where
the effects of bone loading were separated from the influence
of the circulation and other organ systems. Isolated cores of
cancellous bone were perfused with culture fluid and loaded
using the Zetos culture/loading system (18). Although daily
episodes of loading induced mineral accretion and increased
apparent stiffness compared with unloaded bone, the addition
of exogenous recombinant sclerostin inhibited these changes.
Concomitantly, exogenous sclerostin increased the expression
of bone resorption marker genes, such as CA2 and CTSK
mRNA and increased mean osteocyte lacunar size, indicative
of osteocytic osteolysis. Our findings suggest that sclerostin
can block response to mechanical loading in part via direct
actions on osteocyte-controlled mineral accretion and the pro-
motion of osteocytic osteolysis.
MATERIALS AND METHODS
Sample preparation and culture conditions. Cancellous bovine
bone was obtained fresh from the sternum of male cattle less than 2 yr
of age courtesy of a local slaughterhouse. Using a specially designed
diamond-coated hollow drill (Grizzly Industrial, Bellingham, WA),
bone cores with a diameter of 10 mm were drilled out of the bone
slices under sterile conditions. The bone cores were then machined to
5 mm thickness using a plane-parallel saw (5). During the entire
procedure, the saw, drill, and bone were continuously cooled with
sterile saline to prevent thermal necrosis and desiccation. The bone
cores were washed with sterile saline using a dental cleaning device
(Water Pik, Fort Collins, CO) to remove the bone marrow, and then
placed in sterile bone chambers and connected to individual culture
media reservoirs, at 37°C. They were perfused with the mineralizing
cell culture media (7 ml/sample) consisting of Dulbecco’s Modified
Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA) with 20 mM
HEPES, 10% fetal calf serum, 1.8 mM KH2PO4, 100 M L-ascorbate-
2-phosphate, 2 mM L-glutamine, 1.2 mg/ml benzyl-penicillin, 1.6
mg/ml gentamicin sulfate, and 4 g/ml amphotericin B, at a rate of 7
ml/h using a 24-channel planetary drive peristaltic pump (Ismatec IP
24, Ismatec SA, Switzerland). After equilibration for 24 h, bone cores
were perfused in the absence or additional presence of 50 ng/ml
human recombinant sclerostin (rhSCL; R&D Systems, Minneapolis,
MN). The dose of 50 ng/ml rhSCL was chosen based on that we had
already demonstrated to have near-maximal effects on osteoblast/
osteocyte lineage cells in vitro (2, 54). Media with all supplements,
including rhSCL where used, were changed daily throughout the
experimental period and eluates stored at 4°C for analysis.
Mechanical stimulation and measurement of stiffness. Bone cores
were loaded using a second-generation Zetos device, running propri-
etary software (Zetos version 2.0.0.1, Simplex Scientific). Loaded
bone cores received a single episode of 300 cycles of loading per day
at 2,000 microstrain at 1 Hz. The apparent stiffness measured in
megapascals (Young’s modulus) was determined for all bone samples
immediately before applying each daily loading episode, using the
in-built Zetos protocol (18) over a 16- to 18-day experimental period,
as indicated. This consisted of applying a 10-N preload to the bone
cores and then increasing loading to a maximum of 4,000 microstrain,
acquiring 50 measurements of deformation. An additional control
group of bone cores (unloaded control) was cultured identically to the
other groups but without either loading or the addition of rhSCL.
Biochemical analyses. The ionized calcium concentrations in the
culture media were measured using a micro calcium ion electrode
(Lazar Research Laboratories) and a direct UV method (10), respec-
tively, as per manufacturer’s instructions (ThermoFisher Scientific).
The absorbance at 650 nm and 340 nm was measured on a Konelab 30
(ThermoFisher Scientific), respectively. Levels of COOH-terminal
telopeptide of type I collagen (-CTX) in the culture media were
measured by enzyme-linked immunosorbent assay (ELISA) (Immu-
nodiagnostic Systems, Boldon, UK).
Bone histology. Specimens for histology were fixed with 10%
formalin (Asia Pacific Specialty Chemicals) and decalcified with
PBS (pH 8.0) including 1% ethylenediaminetetraacetic acid
(EDTA) disodium salt (Chem-Supply) and 0.5% paraformaldehyde
(PFA; ThermoFisher Scientific) to decalcify samples slowly for
tartrate-resistant acid phosphatase (TRAP) conservation. The sam-
ples were infiltrated and embedded in paraffin after decalcification.
Sections, 5 m thick, were stained by hematoxylin-eosin (H&E),
toluidine blue, and TRAP staining. Images were captured by a
Leica DM6000B microscope (Leica Microsystems, Wetzlar, Ger-
many). Toluidine blue-stained sections were used to measure
osteocyte lacuna size, which was quantified from images using a
Quantimet imaging system (Leica) and ImageJ software, as de-
Table 1. Sequences of oligonucleotide primers for real-time
RT-PCR designed on the basis of published bovine gene
sequences and predicted PCR product sizes
Target Gene Sense Primer Sequence (5=¡3=)
Expected Product
Size, bp
BACT S ACCGTGAGAAGATGACCCAGA 127
AS TCACCGGAGTCCATCACG
SOST S CCCTTTGAGACCAAAGACGC 244
AS CAGGACACAACAGCTGCACC
CA2 S GGAAGAAATATGCTGCCGAGC 194
AS GAAGTCGGTGCTCTTACCCTTTG
TRAP S GCAGCCAAGGAGGACTACGTG 176
AS CCATTCTCATCCTGAAGGTACTGC
CTSK S CCTATCCATATGTTGGACAGGATG 169
AS AAGGAGGTCAGGCTTGCATC
RANKL S CTACTTCCGAGCGCAGATGG 90
AS TCCGTGTTTTCATGGAGCTTG
MEPE S TGACCCTGGCAGCACCAAC 219
AS GCTCTTGACTTCTCTTGCCAGAATG
PHEX S GGGTGTTCGATGGGCCTTTA 217
AS ATACTTGCCGGTTTGCAGGA
S, sense; AS, antisense.
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scribed previously (23). These sections were also used to deter-
mine the percentage of occupied osteocyte lacunae, according to
the number of visible nuclei, stained purple and located within the
lacunae (35).
To visualize the calcium incorporation, bone cores were incubated
with medium containing 3 g/ml calcein (Sigma Chemical, St. Louis,
MO) for 24 h on days 7 and 13 of the experiment. Specimens were
fixed and embedded in methylmethacrylate. Bone blocks were
trimmed and sectioned by microtome (Polycut-E, Leica SP 2600,
Cambridge Instruments, Cambridge, UK). Calcein-labeled regions
were imaged using the Quantimet (Leica) and the degree of calcein
staining was also measured at 9–17 regions of each section, in 3–5
samples for each treatment. Fluorescence intensity was quantified
using ImageJ software.
Osteocyte-like cell cultures. Human primary osteoblast-like cells
were isolated from femoral trabecular bone taken from patients
undergoing primary total hip replacement surgery and cultured ex
vivo, as described previously (3). Samples were obtained with written,
informed consent and approval by the Human Ethics Committee of
the Royal Adelaide Hospital. Cells were cultured under differentiating
conditions for a period of 28 days, which gives rise to cells that
phenotypically resemble mature osteocytes (2, 4, 23, 35). Mature
osteocyte-like cells were cultured for a further 72 h, either untreated
or with the addition of rhSCL, as indicated. Supernatants were
assayed for -CTX levels, as above.
RNA extraction and real-time polymerase chain reaction (PCR).
Extraction of RNA from bone and real-time RT-PCR was conducted,
as described previously (23) with some modifications. Briefly, fol-
lowing the experimental protocol (ex vivo culture with or without
mechanical loading or in the additional presence of rhSCL) bovine
trabecular bone samples were rinsed in PBS, and cut into small pieces
using sterile instruments cleaned with diethylpyrocarbonate (DEPC)-
treated water. Trizol reagent (Life Technologies, Gaithersburg, MD)
was added and the bone pieces were transferred to sterile 1.5-ml
centrifuge tubes and further crushed using the blunt end of a pair of
surgical steel scissors. The samples were frozen at 80°C overnight,
then thawed and centrifuged at 1,000 g for 5 min to pellet any
insoluble material. Total RNA was then isolated as per manufacturer’s
instructions (Life Technologies). Complementary DNA (cDNA) was
synthesized using iScript reagent (Bio-Rad Laboratories, Hercules,
CA), and gene expression was analyzed by real-time RT-PCR using
the SYBR Green incorporation technique. Relative gene expression
between samples was calculated using the comparative cycle thresh-
old method, using bovine actin-beta (ACTB) as a housekeeping gene.
Oligonucleotide primers were designed in-house to flank intron-exon
boundaries, and were purchased from Geneworks (Thebarton). Se-
quences of oligonucleotide primers used are shown in Table 1.
Statistical analysis. Statistical differences between data sets were
assessed using one-way analysis of variance (ANOVA) followed by
A B
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E F
Fig. 1. The effect of bone marrow on perfu-
sion. Bone cores with and without bone mar-
row (n  3/group) were seated in individual
chambers and continuously perfused with me-
dia including Reactive red 120 for 24 h.
Sagittal sections were obtained through the
center of the bone cores with bone marrow
(A) and without bone marrow (B). Specimens
with and without bone marrow were fixed in
10% formaldehyde and decalcified with phos-
phate-buffered saline (pH 8.0) including 1%
EDTA and 0.5% PFA, and cut into 5-m-
thick sections. Samples stained by H&E and
TRAP with bone marrow (C and E) and
without bone marrow (D and F). Arrowheads
indicate osteoblasts and lining cells. Arrows
indicate TRAP-positive osteoclasts. Scale bar,
200 m.
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Tukey’s post hoc test (GraphPad Prism). A value for P  0.05 was
considered significant.
RESULTS
Bone organ culture. The Zetos system comprises a piezo-
electric controlled bone loading device, together with a con-
tinuous flow chamber that perfuses bone samples with culture
medium to maintain bone viability (12). Since the Zetos device
allows controlled physiological loading to be applied to large
animal trabecular bone, we considered it a suitable system, in
which to investigate the effects of sclerostin on mineral accrual
induced by mechanical loading. Since we have established that
osteocytes are target cells for the action of sclerostin (2, 23,
54), we first performed a control experiment to test whether
osteocytes would be exposed to the perfusate. Bone cores with
either an intact marrow or with marrow physically removed
using a dental flossing device were perfused with Reactive Red
120 stain solution. After perfusion for 24 h, the bone cores
were sectioned transversely and longitudinally. Poor dye pen-
etration in bone cores with intact marrow suggested that
perfusion was limited to the periphery (Fig. 1A), whereas
complete dye penetration in cores with marrow removed
showed that cores were perfused throughout (Fig. 1B). Marrow
was therefore removed for all subsequent experiments. Histo-
logical analysis indicated that the flushing of bone marrow
resulted in the removal of most bone lining cells, osteoblasts
(Fig. 1C) and osteoclasts (Fig. 1E), with a significant enrich-
ment of osteocytes in the bone cores (Fig. 1, D and F).
The effect of mechanical loading on SOST mRNA expression.
The expression of sclerostin in bone is reported to be influ-
enced by the local strain perceived by osteocytes, with low
expression under load and higher expression in the unloaded
state (31, 32, 45). This has mainly been examined in cortical
bone in mice. Thus we sought to test whether loading of large
animal trabecular bone also regulates endogenous SOST
mRNA levels. Bone cores were divided into three groups,
unloaded, loaded, and loaded with rhSCL (50 ng/ml) for
periods of 4 h and 7 days, and mRNA of each sample was
prepared for RT-PCR analysis. We observed that 4 h after a
single period of mechanical loading there was a trend for
decreased SOST mRNA expression in comparison to unloaded
bone (data not shown), and after 7 consecutive days of daily
loading SOST expression was reduced by approximately half
compared with unloaded bone samples (Fig. 2). The addition of
exogenous rhSCL had no additional effect on the reduction of
SOST mRNA expression in loaded bone.
Effect of sclerostin on loading-induced stiffness. It has been
demonstrated previously in the Zetos system that loading
changes the mechanical properties of the bone (11, 13, 53). To
elucidate the direct effects of sclerostin on the loading re-
sponse, cores were perfused with medium alone or medium
containing added recombinant sclerostin, and mechanical load
was applied daily. A third group of cores were cultured without
daily loading or the addition of rhSCL. The stiffness (Young’s
modulus) of each bone core was determined each day and in
the case of the loaded groups, before applying mechanical load.
The apparent stiffness in the unloaded group increased slightly
with time, as reported previously (13, 53). In response to daily
loading, the apparent stiffness increased to a greater extent
throughout the experimental period (Fig. 3), as reported pre-
viously (13, 53). However, the effect of loading was signifi-
cantly abrogated by rhSCL treatment. These data show that
sclerostin could attenuate the response to bone loading, most
likely by a direct effect on osteocytes.
Ionic calcium levels in culture media. We have recently
reported that rhSCL promotes osteocyte-mediated release of
calcium from bone (23). To investigate whether these effects of
sclerostin could occur in the context of mechanical loading,
changes in the ionic calcium levels of the culture media were
measured for each individual bone core. There was no detect-
able difference between groups during the first 2 wk of obser-
vation (data not shown), perhaps because of the relatively large
volume of media perfused (7 ml) and the relatively short period
(24 h), over which each sample was collected. However,
media from the loaded  rhSCL group collected in the third
week of culture showed significantly increased ionic cal-
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Fig. 2. SOST mRNA expression in response to loading in the presence or
absence of rhSCL. Bone cores were divided into 3 groups: unloaded, loaded,
and loaded in the presence 50 ng/ml of rhSCL over 7 days. Total RNA of bone
was extracted and real-time RT-PCR was performed for SOST mRNA. Data
are mean mRNA levels normalized to BACT mRNA  SD of triplicate wells.
Significant difference from the unloaded control is indicated.
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Fig. 3. Effects of sclerostin on apparent stiffness. The bone cores were divided
into 3 groups: unloaded controls, loaded controls, and loaded  rhSCL (50
ng/ml). The loading procedure was 300 cycles/day of 2,000 microstrain
applied at a frequency of 1 Hz for 3 wk. The apparent stiffness of each bone
sample was determined daily immediately before the load was applied as
described in MATERIALS AND METHODS. Data are means SE of 8 samples per
group, all obtained from the same bovine sternum. Similar data were obtained
from 3 independent experiments. The regression coefficients (R2) for each
group and significant difference between the groups are indicated.
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cium levels compared with the loaded and unloaded control
samples (Fig. 4).
Calcein incorporation. We reported that treatment of human
mineralizing osteocyte-like cultures with rhSCL in vitro re-
sulted in the inhibition of mineral incorporation into the cell
layer (2). To test the effect of sclerostin on mineral accrual in
the bone cores, calcein was added to perfusates on days 7 and
13 for a period of 24 h in each case and the bone cores
processed for analysis after the 16-day experiment. Calcein
was incorporated into the trabecular bone surfaces in all groups
(Fig. 5). The overall fluorescence intensity of the loaded bone
cores was significantly higher than that in the unloaded group,
indicative of increased dynamic calcium uptake in response to
loading (Fig. 5D). The incorporation of calcein into the bone
cores in the presence of rhSCL (Fig. 5B) was significantly
lower than in the cores perfused with medium alone (Fig. 5A).
Higher power microscopy revealed that calcein labeling was
most prominent on the surfaces of bone, including those of
vascular pores, and within osteocyte lacunae (Fig. 5C), the
latter consistent with osteocytes directly regulating perilacunar
mineral in this system.
Histology. As stated, the predominant cell type remaining in
the trabecular bone cores after flushing was osteocytes (Fig.
1D) and this remained the case after of culture ex vivo, with
histological analysis revealing an apparent absence of both
TRAP-positive osteoclasts (not shown) and osteoblasts (Fig.
6A). Osteocytes showed an evenly spread, noncondensed nu-
cleus, consistent with cell viability, with the cell body often
positioned eccentrically within the lacunae (Fig. 6A). To de-
termine the viability of the remaining osteocytes, we measured
the osteocyte lacunar occupancy. There was ~80% occupancy
of osteocyte lacunae overall, with no significant differences
observed between groups (Fig. 6B). Analysis revealed that the
size of lacunae increased significantly with rhSCL treatment, in
comparison to the cores perfused in medium alone, either
loaded or unloaded (Fig. 6C).
The effect of sclerostin on markers of bone resorption and
formation. To investigate bone resorption in this system, we
analyzed the culture media for the presence of carboxy-termi-
nal cross-linking telopeptides of type I collagen (-CTX).
-CTX levels decreased after the first week of culture, and
increased thereafter (Fig. 6D). After prolonged culture, the
level of -CTX was significantly elevated in the presence of
rhSCL, compared with either unloaded or loaded control cores,
suggesting that rhSCL could enhance the degradation of the
bone matrix. The absence of observable osteoclasts implied
that osteocytes were mediating this process. To test this, we
generated human primary osteocyte-like cultures, consisting of
differentiated cells residing in an endogenous mineralized type
I collagen matrix (2, 4, 23, 35), and treated these cells for 72
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during 1 day culture; significant differences: abetween rhSCL group and
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Fig. 5. Effects of rhSCL on bone mineraliza-
tion. Bovine bone cores were perfused with
calcein and processed for sectioning as de-
scribed in MATERIALS AND METHODS. A: a
cross section of a whole bone core (dimen-
sions 10 mm 	 5 mm) cultured with daily
mechanical loading. B: an example of a bone
core loaded in the presence of rhSCL. C:
labeling at a higher magnification (20	 ob-
jective) showing an example of calcein la-
beling at the trabecular surface (arrowhead)
and a labeled osteocyte lacuna (arrow). D:
quantification of total calcein labeling; data
shown are means of fluorescence inten-
sity  SE. n  5 bone cores group, all ob-
tained from the same bovine sternum. Simi-
lar results were obtained for 2 independent
experiments.
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h with rhSCL. As shown in Fig. 6E, measurably increased
-CTX was released into the culture supernatant in response to
rhSCL at 50 ng/ml.
To investigate the effect of sclerostin on resorption marker
gene expression, we cultured bone cores for 3 days with rhSCL
at concentrations from 1 to 50 ng/ml. Consistent with our
findings in human osteocyte-like cells, MLO-Y4 osteocytes
and in human trabecular bone (23, 54), rhSCL induced the
mRNA expression of the resorption-associated genes TRAP,
cathepsin K, and RANKL (Fig. 7, A–D). Recombinant human
sclerostin treatment also induced the expression of the min-
eralization inhibitory gene MEPE in a dose-dependent man-
ner (Fig. 7E) and decreased the expression of the mineral-
ization promoting gene, phosphate regulating gene with
homologies to endopeptidases on the X-chromosome
(PHEX), at concentrations between 1 and 50 ng/ml (Fig.
7F), consistent with our findings in osteocytes in vitro and
ex vivo (2).
DISCUSSION
Accumulating evidence indicates that sclerostin, which is
predominantly secreted from mature osteocytes, is a local
regulator of bone metabolism. Osteocytes, including preosteo-
cytes, constitute the major cell type in bone and are likely
targets for the activity of sclerostin, based both on in vitro
studies that demonstrate osteocyte sensitivity to sclerostin and
its very localized and regulated expression pattern in bone (2,
23, 54). The expression of sclerostin appears to reflect local
strains perceived by osteocytes, with low production under
mechanical load and high production in the unloaded condition
(31, 32, 45). Sclerostin is known to negatively regulate bone
mass by inhibiting the Wingless integration (Wnt)/-catenin
pathway. Javaheri and colleagues (17) showed that bone for-
mation induced by mechanical loading did not occur in mice
lacking an allele of the -catenin gene, indicating the impor-
tance of the Wnt/-catenin signaling pathway for the effect of
loading. Furthermore, transgenic expression of SOST also an-
tagonized loading-induced bone formation in mice (49). How-
ever, the function of sclerostin in mechanical loading has been
less well characterized in trabecular bone, particularly from
large animals. Here, we sought to determine the effect of
exogenous sclerostin on the response of bovine cancellous
bone to daily episodes of loading. We used a concentration of
rhSCL that we showed previously was near maximal for its
effects on human osteocytes in vitro (2, 54). Although this is
~50–60-fold higher than levels typically found in the circula-
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tion, the local bone fluid concentration of sclerostin deriving
from osteocytes, and to which the responding cells are ex-
posed, is unknown but is likely to be considerably higher than
the circulating level. Consistent with previous reports using a
similar system (13, 53), we observed a significant increase in
stiffness in cyclically loaded bovine trabecular bone ex vivo
compared with baseline and to identically cultured unloaded
controls. In the present study, this was observed in a reduc-
tionist system, with removal of bone marrow and detectable
bone surface cells, and in the absence of functional vasculature,
neural, and endocrine systems. Furthermore, suppression of
endogenous SOST mRNA expression in response to load was
observed, at least over the first 7 days, consistent with in vivo
models (31, 32, 45). Notably, perfusion of bone with rhSCL
suppressed the positive effect of mechanical loading on bone
stiffness.
In seeking a mechanistic explanation for changes in stiff-
ness, we observed, using a calcein surrogate as a marker, a
decreased uptake of calcium in bone loaded in the presence of
exogenous rhSCL compared with loaded control samples. It is
likely that additional mineralization within the bone matrix had
a measurable effect on the stiffness of the bone cores, since
bone mineralization and modulus have been shown to be
positively correlated (14). Parfitt (37) reviewed the literature
relating to calcium exchange between the bone and the extra-
cellular fluid, citing experiments using radiolabeled calcium,
which showed “immediate rapid uptake at all bone surfaces
accessible to the circulation, regardless of their cellular activity
or degree of mineralisation.” This is consistent with the com-
mon observation that bone explants in culture take up calcium
from the medium, likely by simple physicochemical mecha-
nisms. Parfitt (37) described a pool of calcium that is ex-
changeable with bone surfaces, and it has subsequently been
experimentally demonstrated that an osteocyte-mediated
mechanism, driven for example by parathyroid hormone (PTH)
(39), can mobilize calcium (and phosphate) from this pool into
the circulation. Calcium uptake into bone may therefore pro-
ceed by a simple physicochemical mechanism, with its release
being controlled by osteocytes, which are in turn regulated by
mediators, such as PTH and, as we have shown previously (2),
sclerostin. This mechanism relies on viable osteocytes and it
has been shown that osteocyte death is associated with miner-
alizing osteocyte lacunae (6, 7).
We have recently demonstrated that rhSCL induced the
expression by osteocytes of a number of mediators previously
associated with bone resorption by osteoclasts. These included
RANKL, carbonic anhydrase 2, cathepsin K, and TRAP (23).
A similar panel of genes was shown to be associated with
osteocytic osteolysis during lactation (41). We have identified
that sclerostin also regulates osteocyte-mediated bone miner-
alization through regulation of the PHEX/MEPE axis, and that
the upregulation by sclerostin of MEPE and MEPE-ASARM
peptides was critical to the inhibitory effect of sclerostin (2).
Sclerostin treatment of bovine bone upregulated the expression
of MEPE mRNA and inhibited the expression of PHEX
mRNA, consistent with our report in human bone (2). The
combined regulation of these mineralization-associated pro-
teins by sclerostin could provide cell-mediated control of the
perilacunar mineralization and serve as a prelude to removal of
the organic matrix, the latter evidenced by the release of
-CTX from the bone cores. Strong confirmatory evidence for
this was obtained using differentiated cultures of human pri-
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mary osteocyte-like cells, where we show for the first time the
release of -CTX by the activity of osteocytes in response to
sclerostin. This is consistent with, and appears to result in, the
enlargement of the osteocyte lacuna size in the rhSCL-treated
bone. This is also consistent with our previous observations of
the effect of sclerostin in human trabecular bone (23), and
provides the first direct evidence that sclerostin can effect
collagen breakdown by its actions on osteocytes and can do so
even when trabecular bone is mechanically loaded. Interest-
ingly, the osteocyte lacunar size in loaded  rhSCL-treated
samples was significantly larger than that in both loaded and
unloaded groups, and indeed there was no difference in this
parameter in these two groups, consistent with the reports by
others that significant osteocytic osteolysis does not seem to
occur in response to mechanical unloading (29, 41). On the
other hand, dramatic changes in osteocyte morphology oc-
curred after spinal cord injury in rats, which could be prevented
by treatment with neutralizing sclerostin antibodies (40). It
appears that altered lacunocanalicular morphology has impli-
cations for the mechanical properties of bone. For example, it
was elegantly shown in lactating rats that the bone elastic
modulus decreased inversely with the increase in osteocyte
lacunocanalicular porosity (19), consistent with the reduced
gain in modulus seen in the present experiments with rhSCL
treatment. Thus it is conceivable that the mechanical loading-
induced reduction of endogenous sclerostin expression serves
to stabilize the perilacunar matrix.
In summary, we propose that our observations are consistent
with the notion of passive uptake by bone of calcium, which is
maintained in balance by osteocytes, and that loading results in
increased mineral incorporation into the periosteocyte matrix.
Sclerostin, by an as yet undetermined mechanism, causes the
release by osteocytes of bone matrix resorptive molecules,
thereby reducing the effects of loading on mineral accrual. It is
not known whether these experimental observations with ex-
ogenous sclerostin are reflective of physiological or patholog-
ical processes. However, increased levels of sclerostin in bone,
as might be caused by inflammation (52) for example, could
reduce the anabolic effects of mechanical loading. The contri-
bution of osteocytes to circulating -CTX, a major serum bone
turnover marker, in vivo is an interesting area of future re-
search. Our findings are of potential relevance to the mecha-
nism of action of sclerostin-targeting therapies, since -CTX
levels are strongly suppressed in individuals receiving scleros-
tin-neutralizing antibodies (36, 43).
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